Primary Sjogren's Disease

1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Vor Biopharma
Vor BiopharmaMA - Cambridge
1 program
1
TelitaciceptPhase 31 trial
Active Trials
NCT07404865Recruiting250Est. Aug 2028

Trial Timeline

Clinical trial activity over time

2026
2027
2028
Vor BiopharmaTelitacicept

Clinical Trials (1)

Total enrollment: 250 patients across 1 trials

NCT07404865Vor BiopharmaTelitacicept

Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

Start: Feb 2026Est. completion: Aug 2028250 patients
Phase 3Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 250 patients
1 companies competing in this space